Article Sidebar
Published:
Sep 5, 2016Keywords:
Article Details
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.
Main Article Content
Clinical effects of low-molecular-weight heparin combined with ulinastatin in children with acute pancreatitis
Abstract
Purpose: To explore the clinical effects of low-molecular-weight heparin (LMWH) combined with ulinastatin (UTI) in children with acute pancreatitis.
Methods: In total, 560 patients with severe acute pancreatitis treated at Binzhou People’s Hospital, Shandong, China, from April 2012 to June 2014 were enrolled in this study. They were divided into control (280 patients, ulinastatin + conventional treatment) and observational groups (280 patients, LMWH + ulinastatin + conventional treatment). The treatment lasted for 2 weeks. Clinical parameters, laboratory test indices, Acute Physiology and Chronic Health Evaluation (APACHE II) score, and computed tomography score of pancreatic necrosis (CTSPN) were assessed in both groups.
Results: On admission, no significant differences were noted in clinical features, laboratory parameters, APACHE II scores, or CTSPN between the two groups (all p > 0.05). After 2 weeks of treatment, serum amylase, urine amylase, prothrombin time, fibrinogen, partial thromboplastin time, and platelet count in the study group were 913 ± 281 U/L, 1893 ± 295 U/L, 16 ± 1.60 s, 3 ± 0.60 g/L, 39.80 ± 5.60 s, and 294 ± 49 × 109/L, respectively, all of which were similar or superior to those in the control group (1738 ± 346 U/L, 2453 ± 473 U/L, 15 ± 1.50 S, 2.50 ± 0.50, 39.80 ± 5.90, and 192 ± 37 × 109/L)). APACHE II scores and CTSPN after 2 weeks of treatment in the observation group were 8.50 ± 1.80 and 2.10 ± 1, respectively, which were superior to those in the control group (9.60 ± 2.40 and 4.30 ± 2.60, respectively; p < 0.05). Moreover, the incidence of complications, mortality rate, and average duration of the hospital stay in the observation group were lower than those in the control group (p > 0.05). The cure rate in the observation group was higher than that in the control group.
Conclusions: LMWH combined with UTI enhances the efficacy of conventional treatment and reduces mortality. Thus, it is a potentially effective treatment strategy for severe acute pancreatitis in children.
Keywords: Acute pancreatitis, Low-molecular-weight heparin, Multiple organ function syndrome, APACHE II score, Pancreatic necrosis
